Skip to main content
SpringerLink
Log in

Necessity of Using Intermediate Outcomes to Proxy Long Term Effects

The Example of Thrombolytics

  • Leading Article
  • Proxy Outcomes for Long Term Effects
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hurley SE Indices of therapeutic outcome in pharmacoeconomic evaluation of drug therapy. PharmacoEconomics 1992; 1: 155–60

    Article  PubMed  CAS  Google Scholar 

  2. Lewis NJW, Patwell JT, Briesacher BA. The role of insurance claims databases in drug therapy outcomes research. PharmacoEconomics 1993; 4: 323–30

    Article  PubMed  CAS  Google Scholar 

  3. Second International Study of Infarct Survival (lSIS–2) Collaborative Group. Randomized trial of intravenous streptokinase,oral aspirin, both or neither among 17,187 cases of suspectedacute myocardial infarction. Lancet 1988; 2: 349–60

    PubMed  Google Scholar 

  4. Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytictreatment in acute myocardial infarction. Lancet 1986; l: 397–401

    Google Scholar 

  5. Van der Werf F, Arnold AER, The European Cooperative Study Group for Recombinant Tissue–Type Plasminogen Activator. Intravenous tissue plasminogen activator and size of infarct,left ventricular function, and survival in acute myocardial infarction. BMJ 1988; 297: 1374–9

    Article  PubMed  Google Scholar 

  6. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardialinfarction. Anglo–Scandinavian Study of Early Thrombolysis(ASSET). Lancet 1988; 2: 525–30

    Article  PubMed  CAS  Google Scholar 

  7. Gruppo Italiano per lo Studio della Streptochinasi neIr Infarto Miocardico (GISSI). GISSI–2: a factorial randomised trial ofalteplase versus streptokinase and heparin versus no heparinamong 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71

    PubMed  Google Scholar 

  8. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Article  PubMed  Google Scholar 

  9. International Study Group. In–hospital mortality and clinical course of 20 819 patients with suspected acute myocardialinfarction randomised between alteplase and streptokinasewith or without heparin. Lancet 1990; 336: 71–5

    Article  PubMed  Google Scholar 

  10. International Study of Infarct Survival (lSIS) Collaborative Group. ISIS–3: a randomised comparison of streptokinase vstissue plasminogen activator vs anistreplase and of aspirinplus heparin vs aspirin alone among 41 299 cases of suspectedacute myocardial infarction. Lancet 1992; 339: 753–70

    Article  PubMed  Google Scholar 

  11. Battershill PE, Benfield P, Goa KL. Streptokinase: a review of its pharmacology and therapeutic efficacy in acute myocardialinfarction in older patients. Drugs Aging 1994; 4: 63–86

    Article  PubMed  CAS  Google Scholar 

  12. Collen D, Lijnen HR, Todd PA, et al. Tissue—type plasminogen activator: a review of its pharmacology and therapeutic useas a thrombolytic agent. Drugs 1989; 38: 346–88

    Article  PubMed  CAS  Google Scholar 

  13. Braunweld E, editor. Heart disease: a textbook of cardiovascular medicine. Chap. 89. Philadelphia: WB Saunders Co., 1992: 1231–5

  14. Detsky AS. Using cost—effectiveness analysis for formulary decision making: from theory into practice. PharmacoEconomics 1994; 6: 281–8

    PubMed  CAS  Google Scholar 

  15. Bargent C, Collins R, For the International Study of Infarct SurvivaI (lSIS) Collaborative Group. ISIS–2: 4–year mortalityfollow–up of 17 189 patients after fibrinolytic and antiplatelettherapy in suspected acute myocardial infarction [abstract]. Circulation 1993; 88: 1291

    Google Scholar 

  16. Califf RM, Mark DB, Wagner GS. Acute coronary care in the thrombolytic era. Chap. 38. Chicago: Year Book MedicaIPublishers Inc., 1988: 548–58

  17. Cupples LA, Gagnon DR, Wong ND. Preexisting cardiovascular conditions and long–term prognosis after initial myocardialinfarction. The Framingham study. Am Heart J 1993; 125: 863–72

    Article  PubMed  CAS  Google Scholar 

  18. Berger CJ, Murabito JM, Evans JC, et al. Prognosis after first myocardial infarction. Comparison of Q–wave and non–Qwavemyocardial infarction in the Framingham Heart Study. JAMA 1992; 268: 1545–51

    Article  PubMed  CAS  Google Scholar 

  19. Law EA, Gajewski J, editors. MedicaI risks: trends in mortality by age and time elapsed. VoI. I. Chap 6. New York: Praeges, 1990: 104–6

  20. Schwartz JS, Vanscoy G, Lee JH. Healthcare economics: the new tool for clinical decision making. Pittsburgh: Universityof Pittsburgh, 1994

  21. Cooke J. The practical impact of pharmacoeconomics on institutional managers. PharmacoEconomics 1994; 6: 289–97

    PubMed  CAS  Google Scholar 

  22. Pelc A. Presenting economic information for decision making. PharmacoEconomics 1994; 6: 346–51

    Article  PubMed  CAS  Google Scholar 

  23. Davey P, Malek M. The impact of pharmacoeconomics on the practitioner and the patient: a conflict of interests? PharmacoEconomics 1994; 6: 298–309

    PubMed  CAS  Google Scholar 

  24. Bloom BS, Hillman AL, Fendrick AM, et al. A reappraisal of hepatitis B virus vaccination policy using cost–effectivenessanalysis. Ann Intern Med 1993; 118: 298–306

    PubMed  CAS  Google Scholar 

  25. Hillman AL, Bloom BS, Fendrick AM, et al. Management of gastroesophageal reflux disease: a cost–effectiveness analysis. Arch Intern Med 1992; 152: 1461–72

    Article  Google Scholar 

  26. Gunning-Schepers LJ, Ravenbregt JJ, Van der Maas PJ. Population interventions reassessed. Lancet 1989; l: 479–83

    Article  Google Scholar 

  27. Glick H, Heyse J, Thompson D, et al. A model for evaluating the cost effectiveness of cholesterol–Iowering treatments. Int J Tech Assess Health Care 1992; 8: 719–34

    Article  CAS  Google Scholar 

  28. Hillman AL, Eisenberg JM, Pauly MV, et al. Pharmaceutical company–sponsored economie analysis. N Engl J Med 1991; 324: 1362–5

    Article  PubMed  CAS  Google Scholar 

  29. Kassirer JP, Angell M. The Journal’s policy on cost–effectiveness analyses. N Engl J Med 1994; 331: 669–70

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, 3641 Locust Walk, Philadelphia, PA 19104-6218, USA

    J. Sanford Schwartz

Authors
  1. J. Sanford Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, J.S. Necessity of Using Intermediate Outcomes to Proxy Long Term Effects. Pharmacoeconomics 7, 7–13 (1995). https://doi.org/10.2165/00019053-199507010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199507010-00002

Keywords

Search

Navigation